The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Savannah Mendoza used to spend most of her paychecks on food delivery apps and at fast food drive-thrus, trying to satisfy a ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

I put the shot away." Dog the Bounty Hunter's daughter shared Nov. 1 that she had lost 58 pounds in 10 months thanks to a change in diet and the use of the weight loss medication Tirzepatide, adding, ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...